DAMORA THERAPEUTICS, INC. Earnings Per Share (Diluted)
DAMORA THERAPEUTICS, INC. (DMRA) reported Earnings Per Share (Diluted) of -$0.39 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.39.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.62.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$135.60.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$2.36.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was $3.98.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was -$18.53.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$36.08.
- DAMORA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$2.43.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.39 10-Q · filed 2026-08-10 | -$0.79 10-Q · filed 2026-08-10 | -$8.04 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$10.70 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2026-03-31 | -$0.62 10-Q · filed 2026-05-12 | -$12.77 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$18.73 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$24.47 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2025-12-31 | -$135.60 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$145.24 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$150.59 derived: net income ÷ weighted average shares · filed 2026-08-10 | $3.98 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$2.36 10-Q · filed 2025-11-06 | -$4.96 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$6.88 10-Q · filed 2025-11-06 | -$11.99 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2025-06-30 | -$2.60 10-Q · filed 2026-08-10 | -$4.51 10-Q · filed 2026-08-10 | -$9.63 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$13.01 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2025-03-31 | -$1.92 10-Q · filed 2026-05-12 | -$7.04 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$10.44 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$15.20 derived: net income ÷ weighted average shares · filed 2026-05-12 | ||||
| 2024-12-31 | -$5.13 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$8.64 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$13.51 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$18.53 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$3.39 10-Q · filed 2025-11-06 | -$8.27 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$13.30 10-Q · filed 2025-11-06 | -$19.25 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||||
| 2024-06-30 | -$4.92 10-Q · filed 2025-08-05 | -$0.20 10-Q · filed 2024-08-12 | -$9.97 10-Q · filed 2025-08-05 | -$0.40 10-Q · filed 2024-08-12 | -$15.94 derived: net income ÷ weighted average shares · filed 2025-08-05 | -$23.45 derived: net income ÷ weighted average shares · filed 2025-08-05 | ||
| 2024-03-31 | -$5.05 10-Q · filed 2025-05-08 | -$0.20 10-Q · filed 2024-04-29 | -$11.02 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$18.52 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$4.16 derived: net income ÷ weighted average shares · filed 2025-05-08 | |||
| 2023-12-31 | -$5.97 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$13.47 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$2.66 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$36.08 10-K · filed 2025-03-19 | -$1.44 10-K · filed 2024-03-08 | |||
| 2023-09-30 | -$7.50 10-Q · filed 2024-11-01 | -$0.30 10-Q · filed 2023-11-06 | -$1.38 derived: net income ÷ weighted average shares · filed 2024-11-01 | -$30.19 10-Q · filed 2024-11-01 | -$1.21 10-Q · filed 2023-11-06 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-11-01 | ||
| 2023-06-30 | -$0.41 10-Q · filed 2024-08-12 | -$0.91 10-Q · filed 2024-08-12 | -$1.46 derived: net income ÷ weighted average shares · filed 2024-08-12 | -$2.00 derived: net income ÷ weighted average shares · filed 2024-08-12 | ||||
| 2023-03-31 | -$0.51 10-Q · filed 2024-04-29 | -$1.06 derived: net income ÷ weighted average shares · filed 2024-04-29 | -$1.59 derived: net income ÷ weighted average shares · filed 2024-04-29 | -$2.26 derived: net income ÷ weighted average shares · filed 2024-04-29 | ||||
| 2022-12-31 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$1.09 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$1.76 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$2.43 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | -$0.54 10-Q · filed 2023-11-06 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.88 10-Q · filed 2023-11-06 | -$2.41 derived: net income ÷ weighted average shares · filed 2023-11-06 | ||||
| 2022-06-30 | -$0.67 10-Q · filed 2023-07-31 | -$1.34 10-Q · filed 2023-07-31 | -$1.87 derived: net income ÷ weighted average shares · filed 2023-07-31 | -$2.37 derived: net income ÷ weighted average shares · filed 2023-07-31 | ||||
| 2022-03-31 | -$0.67 10-Q · filed 2023-04-28 | -$1.20 derived: net income ÷ weighted average shares · filed 2023-04-28 | -$1.70 derived: net income ÷ weighted average shares · filed 2023-04-28 | |||||
| 2021-12-31 | -$0.53 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$2.05 10-K · filed 2023-03-09 | |||||
| 2021-09-30 | -$0.50 10-Q · filed 2022-11-08 | -$1.52 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |